OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The...OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The goal of this article is to evaluate comprehensively the efficacy and safety of nerve growth factor for the treatment of neurological diseases. DATA RETRIEVAL： A computer-based retrieval was performed from six databases, including the Cochrane Library, PubMed, EMBASE, Sino Med, CNKI, and the VIP database, searching from the clinical establishment of nerve growth factor for treatment until December 31, 2013. The key words for the searches were ＂nerve growth factor, randomized controlled trials＂ in Chinese and in English. DATA SELECTION： Inclusion criteria： any study published in English or Chinese referring to randomized controlled trials of nerve growth factor; patients with neurological diseases such as peripheral nerve injury, central nerve injury, cranial neuropathy, and nervous system infections; patients older than 7 years; similar research methods and outcomes assessing symptoms; and measurement of nerve conduction velocities. The meta-analysis was conducted using Review Manager 5.2.3 software. MAIN OUTCOME MEASURES： The total effective rate, the incidence of adverse effects, and the nerve conduction velocity were recorded for each study. RESULTS： Sixty-four studies involving 6,297 patients with neurological diseases were included. The total effective rate in the group treated with nerve growth factor was significantly higher than that in the control group （P 〈 0.0001, RR： 1.35, 95%CI： 1.30-1.40）. The average nerve conduction velocity in the nerve growth factor group was significantly higher than that in the control group （P 〈 0.00001, MD. 4.59 m/s, 95%CI： 4.12-5.06）. The incidence of pain or sclero- ma at the injection site in the nerve growth factor group was also higher than that in the control group （P 〈 0.00001, RR： 6.30, 95%CI： 3.53-11.27）, but such adverse effects were mild. CONCLUSION： Nerve growth factor can significantly improve nerve function in patients with nervous system disease and is safe and effective.展开更多
Objective: To compare the efficacy of a short messaging service (SMS) text messaging and phone reminder to im-prove attendance rates at a health promotion center. Methods: A total of 1 859 participants who had schedul...Objective: To compare the efficacy of a short messaging service (SMS) text messaging and phone reminder to im-prove attendance rates at a health promotion center. Methods: A total of 1 859 participants who had scheduled appointments in the health promotion center of our hospital from April 2007 to May 2007 were enrolled in the study and randomly assigned into 3 groups: control (no reminder) group,SMS text messaging reminder group and telephone reminder group. Attendance rates and costs of interventions were collected. Results: A total of 1848 participants were eligible for analysis. Attendance rates of control,SMS and telephone groups were 80.5%,87.5% and 88.3%,respectively. The attendance rates were significantly higher in SMS and telephone groups than that in the control group,with odds ratio 1.698,95% confidence interval 1.224 to 2.316,P=0.001 in the SMS group,and odds ratio 1.829,95% confidence interval 1.333 to 2.509,P<0.001 in the telephone group. However,there was no difference between the SMS group and the telephone group (P=0.670). The cost effectiveness analysis showed that the cost per attendance for the SMS group (0.31 Yuan) was significantly lower than that for the telephone group (0.48 Yuan). Conclusion: SMS and telephone are effective reminders for improving attendance rate at a health promotion center. SMS reminder may be more cost-effective compared with the telephone reminder.展开更多
Objective To observe the clinical effect of acupuncture in combination with medicine in the treatment of mild cognitive impairment after cerebral infarction as well as the impact on patients＇ daily living ability. Me...Objective To observe the clinical effect of acupuncture in combination with medicine in the treatment of mild cognitive impairment after cerebral infarction as well as the impact on patients＇ daily living ability. Methods Seventy-two patients, in accordance with random number table, were divided into two groups, acupuncture combined with western medicine group （group A） and western medicine group （group B）, each group with 36 patients. In combination with nimodipine tablets, acupuncture which can regulate the mind and reinforce the intelligence [making Baihui （百会 GV 20）, Sishencong （四神聪EX-HN 1）, Sibai （四白 ST 2）, Fengchi （风池 GB 20）, Wanggu （完骨 GB 12）, Tianzhu （天柱 BL 10）, Shenmen （神门 HT 7）, Neiguan （内关 PC 6）, Shuigou （水沟 GV 26）, Sanyinjiao （三阴交 SP 6）, Taichong （太冲 LR 3）, Fenglong （丰隆 ST 40） as the main acupoints] was given in the treatment group （group A） while only nimodipine tablets were given in the control group （group B）. The efficacy of these two groups was evaluated by Montreal Cognitive Assessment （MoCA） Scale after the continuous treatment for three months. Results The remarkably effective rate was 69.4%.and the total effective rate was 91.7% in the treatment group, while the remarkably effective rate was 55.6% and the total effective rate was 80.6% in the control group; the differences between the two groups were statistically significant （P〈0.05）. When comparing the MoCA score before and after treatment, which was 20.23±4.67 before treatment and 26.84±3.87 after treatment in group A; 19.82±3.56 before treatment and 23.33±2.78 after treatment in group B, it was found that the score for both groups became higher after treatment than that before treatment. Furthermore, the increase of the score was higher in the treatment group （6.61±0.80） than that in the control group （3.51±0.78） and the differences were statistically significant （P〈0.05）. Conclusion Acupuncture, which can regulate the mind and reinforce the intelligence, combined with nimodipine tablets is an effective therapy for the treatment of mild cognitive impairment after cerebral infarction, which is superior to single treatment with nimodipine tablets.展开更多
目的:评价新近开发的抗感冒中药治疗急性上呼吸道感染(普通感冒)的疗效和安全性。方法:收集中药治疗急性上呼吸道感染(普通感冒)随机对照试验文献,对符合纳入标准的文献按Jadad计分表评价其质量,对纳入的试验作系统评价,同时按中医感冒...目的:评价新近开发的抗感冒中药治疗急性上呼吸道感染(普通感冒)的疗效和安全性。方法:收集中药治疗急性上呼吸道感染(普通感冒)随机对照试验文献,对符合纳入标准的文献按Jadad计分表评价其质量,对纳入的试验作系统评价,同时按中医感冒病的辨证分型进行分层分析。结果:符合纳入标准的文献共13篇。Meta分析结果显示,中药治疗组与对照组相比,显效率相对危险度(relative risk,RR)为1.10,95%可信区间(confidence interval,CI)[1.05,1.16],两组指标比较,差异有统计学意义(P=0.0002)。降温起效时间加权均数差(weighted mean difference,WMD)为-1.70,95%CI[-2.76,-0.65],两组指标比较,差异有统计学意义(P=0.002)。体温解热时间WMD为-1.32,95%CI[-3.14,0.49],两组指标比较,差异无统计学意义(P=0.15)。亚组分型显示,风热感冒中药治疗组与对照组相比,显效率RR为1.11,95%CI[1.05,1.19],两组指标比较,差异有统计学意义(P=0.0007);风寒感冒中药治疗组与对照组相比,显效率RR为1.07,95%CI[0.99,1.16],两组指标比较,差异无统计学意义(P=0.10)。未报道与中药临床应用相关的严重不良反应。结论:近几年来新开发的抗感冒中药较既往抗感冒中药能够明显提高降温起效时间,更好地改善患者的全身症状,具有起效快、疗效好的特点,未见明显的不良反应。由于所纳入的文献无一篇使用安慰剂,尚需开展使用安慰剂对照的高质量研究。展开更多
目的:分析温肾类汤剂治疗PMOP的疗效和可能发生的不良反应。方法:电子检索9个国内外相关数据库,检索日期截止至2015年9月,并根据Cochrane Handbook 5.1评价标准和工具评价纳入研究的质量,并用Rev Man 5.3软件进行Meta分析。结果:共纳入4...目的:分析温肾类汤剂治疗PMOP的疗效和可能发生的不良反应。方法:电子检索9个国内外相关数据库,检索日期截止至2015年9月,并根据Cochrane Handbook 5.1评价标准和工具评价纳入研究的质量,并用Rev Man 5.3软件进行Meta分析。结果:共纳入44项研究包括3878例患者,多数温肾类汤剂在提高患者血清雌二醇水平方面可能优于常规西药治疗,如疗程6个月时,温肾类汤剂对比常规西药提高患者血清雌二醇水平的WMD和95%CI为[3.2(0.43,5.97)];温肾类汤剂提高机体各部位骨密度水平可能优于温肾类中成药治疗,如疗程6个月时温肾类汤剂对比温肾类中成药提高患者腰椎骨密度WMD和95%CI为[1.38(0.13,1.63)];在调节患者血磷、血钙水平方面,因研究数较少或结论不一致尚未发现较明显的趋势。此外,温肾类汤剂治疗时未发现明显副作用。结论:依据现有临床研究资料分析温肾类汤剂治疗PMOP有临床意义,以温补肾阳为具体治法有一定疗效,汤剂较成药对部分症状的改善效果更佳。但因纳入研究质量以及临床疗效证据十分有限,需要更多设计严谨、实施严格、规模较大的临床研究加以证实。展开更多
基金supported by the National Science and Technology Major Projects for "Major New Drugs Innovation and Development",No.2012ZX09201-301-005
文摘OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The goal of this article is to evaluate comprehensively the efficacy and safety of nerve growth factor for the treatment of neurological diseases. DATA RETRIEVAL： A computer-based retrieval was performed from six databases, including the Cochrane Library, PubMed, EMBASE, Sino Med, CNKI, and the VIP database, searching from the clinical establishment of nerve growth factor for treatment until December 31, 2013. The key words for the searches were ＂nerve growth factor, randomized controlled trials＂ in Chinese and in English. DATA SELECTION： Inclusion criteria： any study published in English or Chinese referring to randomized controlled trials of nerve growth factor; patients with neurological diseases such as peripheral nerve injury, central nerve injury, cranial neuropathy, and nervous system infections; patients older than 7 years; similar research methods and outcomes assessing symptoms; and measurement of nerve conduction velocities. The meta-analysis was conducted using Review Manager 5.2.3 software. MAIN OUTCOME MEASURES： The total effective rate, the incidence of adverse effects, and the nerve conduction velocity were recorded for each study. RESULTS： Sixty-four studies involving 6,297 patients with neurological diseases were included. The total effective rate in the group treated with nerve growth factor was significantly higher than that in the control group （P 〈 0.0001, RR： 1.35, 95%CI： 1.30-1.40）. The average nerve conduction velocity in the nerve growth factor group was significantly higher than that in the control group （P 〈 0.00001, MD. 4.59 m/s, 95%CI： 4.12-5.06）. The incidence of pain or sclero- ma at the injection site in the nerve growth factor group was also higher than that in the control group （P 〈 0.00001, RR： 6.30, 95%CI： 3.53-11.27）, but such adverse effects were mild. CONCLUSION： Nerve growth factor can significantly improve nerve function in patients with nervous system disease and is safe and effective.
基金Project supported by the Health Promotion Center of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, China
文摘Objective: To compare the efficacy of a short messaging service (SMS) text messaging and phone reminder to im-prove attendance rates at a health promotion center. Methods: A total of 1 859 participants who had scheduled appointments in the health promotion center of our hospital from April 2007 to May 2007 were enrolled in the study and randomly assigned into 3 groups: control (no reminder) group,SMS text messaging reminder group and telephone reminder group. Attendance rates and costs of interventions were collected. Results: A total of 1848 participants were eligible for analysis. Attendance rates of control,SMS and telephone groups were 80.5%,87.5% and 88.3%,respectively. The attendance rates were significantly higher in SMS and telephone groups than that in the control group,with odds ratio 1.698,95% confidence interval 1.224 to 2.316,P=0.001 in the SMS group,and odds ratio 1.829,95% confidence interval 1.333 to 2.509,P<0.001 in the telephone group. However,there was no difference between the SMS group and the telephone group (P=0.670). The cost effectiveness analysis showed that the cost per attendance for the SMS group (0.31 Yuan) was significantly lower than that for the telephone group (0.48 Yuan). Conclusion: SMS and telephone are effective reminders for improving attendance rate at a health promotion center. SMS reminder may be more cost-effective compared with the telephone reminder.
基金Supported by Special Research Project for Practice Development of National TCM Clinical Research Base,State Administration of Traditional Chinese Medicine(JDZX 2012139)
文摘Objective To observe the clinical effect of acupuncture in combination with medicine in the treatment of mild cognitive impairment after cerebral infarction as well as the impact on patients＇ daily living ability. Methods Seventy-two patients, in accordance with random number table, were divided into two groups, acupuncture combined with western medicine group （group A） and western medicine group （group B）, each group with 36 patients. In combination with nimodipine tablets, acupuncture which can regulate the mind and reinforce the intelligence [making Baihui （百会 GV 20）, Sishencong （四神聪EX-HN 1）, Sibai （四白 ST 2）, Fengchi （风池 GB 20）, Wanggu （完骨 GB 12）, Tianzhu （天柱 BL 10）, Shenmen （神门 HT 7）, Neiguan （内关 PC 6）, Shuigou （水沟 GV 26）, Sanyinjiao （三阴交 SP 6）, Taichong （太冲 LR 3）, Fenglong （丰隆 ST 40） as the main acupoints] was given in the treatment group （group A） while only nimodipine tablets were given in the control group （group B）. The efficacy of these two groups was evaluated by Montreal Cognitive Assessment （MoCA） Scale after the continuous treatment for three months. Results The remarkably effective rate was 69.4%.and the total effective rate was 91.7% in the treatment group, while the remarkably effective rate was 55.6% and the total effective rate was 80.6% in the control group; the differences between the two groups were statistically significant （P〈0.05）. When comparing the MoCA score before and after treatment, which was 20.23±4.67 before treatment and 26.84±3.87 after treatment in group A; 19.82±3.56 before treatment and 23.33±2.78 after treatment in group B, it was found that the score for both groups became higher after treatment than that before treatment. Furthermore, the increase of the score was higher in the treatment group （6.61±0.80） than that in the control group （3.51±0.78） and the differences were statistically significant （P〈0.05）. Conclusion Acupuncture, which can regulate the mind and reinforce the intelligence, combined with nimodipine tablets is an effective therapy for the treatment of mild cognitive impairment after cerebral infarction, which is superior to single treatment with nimodipine tablets.
文摘目的:评价新近开发的抗感冒中药治疗急性上呼吸道感染(普通感冒)的疗效和安全性。方法:收集中药治疗急性上呼吸道感染(普通感冒)随机对照试验文献,对符合纳入标准的文献按Jadad计分表评价其质量,对纳入的试验作系统评价,同时按中医感冒病的辨证分型进行分层分析。结果:符合纳入标准的文献共13篇。Meta分析结果显示,中药治疗组与对照组相比,显效率相对危险度(relative risk,RR)为1.10,95%可信区间(confidence interval,CI)[1.05,1.16],两组指标比较,差异有统计学意义(P=0.0002)。降温起效时间加权均数差(weighted mean difference,WMD)为-1.70,95%CI[-2.76,-0.65],两组指标比较,差异有统计学意义(P=0.002)。体温解热时间WMD为-1.32,95%CI[-3.14,0.49],两组指标比较,差异无统计学意义(P=0.15)。亚组分型显示,风热感冒中药治疗组与对照组相比,显效率RR为1.11,95%CI[1.05,1.19],两组指标比较,差异有统计学意义(P=0.0007);风寒感冒中药治疗组与对照组相比,显效率RR为1.07,95%CI[0.99,1.16],两组指标比较,差异无统计学意义(P=0.10)。未报道与中药临床应用相关的严重不良反应。结论:近几年来新开发的抗感冒中药较既往抗感冒中药能够明显提高降温起效时间,更好地改善患者的全身症状,具有起效快、疗效好的特点,未见明显的不良反应。由于所纳入的文献无一篇使用安慰剂,尚需开展使用安慰剂对照的高质量研究。
文摘目的:分析温肾类汤剂治疗PMOP的疗效和可能发生的不良反应。方法:电子检索9个国内外相关数据库,检索日期截止至2015年9月,并根据Cochrane Handbook 5.1评价标准和工具评价纳入研究的质量,并用Rev Man 5.3软件进行Meta分析。结果:共纳入44项研究包括3878例患者,多数温肾类汤剂在提高患者血清雌二醇水平方面可能优于常规西药治疗,如疗程6个月时,温肾类汤剂对比常规西药提高患者血清雌二醇水平的WMD和95%CI为[3.2(0.43,5.97)];温肾类汤剂提高机体各部位骨密度水平可能优于温肾类中成药治疗,如疗程6个月时温肾类汤剂对比温肾类中成药提高患者腰椎骨密度WMD和95%CI为[1.38(0.13,1.63)];在调节患者血磷、血钙水平方面,因研究数较少或结论不一致尚未发现较明显的趋势。此外,温肾类汤剂治疗时未发现明显副作用。结论:依据现有临床研究资料分析温肾类汤剂治疗PMOP有临床意义,以温补肾阳为具体治法有一定疗效,汤剂较成药对部分症状的改善效果更佳。但因纳入研究质量以及临床疗效证据十分有限,需要更多设计严谨、实施严格、规模较大的临床研究加以证实。
